A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1695 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharmaceuticals Inc. | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1715 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Berinert 1500 | Csl Behring Canada Inc | kit; Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1717 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Cinryze | Viropharma Biologics Inc | Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1720 | Th1172 | Coagulation Factor XIII A-Subunit (Recombinant) | NA Full view | 0 | Ia | Hematological Disorders | Tretten | Novo Nordisk Canada Inc | Powder for Solution | Intravenous | NA | NA |
| 1722 | Th1173 | Conestat alfa | NA Full view | 0 | Ia | Genetic Disorders | Ruconest | Pharming; Santarus, Inc. | Powder for Solution | Intravenous | NA | NA |
| 1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1729 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly and Company | Solution, Injection | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1730 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly Canada Inc | Solution | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
| 1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
| 1738 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | NA | NA | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | SLAM family member 7 |
| 1739 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 8 |
| 1740 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 9 |
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
| 1745 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Riastap | Csl Behring Gmb H | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1753 | Th1181 | Filgrastim-sndz | NA Full view | 0 | IIIc | Cancer | Zarxio | Sandoz Inc | Solution | Intravenous; Subcutaneous | NA | NA |
| 1758 | Th1183 | Hepatitis B immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Hepagam B | Cangene Bio Pharma Inc. | Injection, Solution | Intramuscular; Intravenous | NA | HBsAg |
| 1769 | Th1186 | Human rabies virus immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Hyperrab S/d | Grifols Therapeutics Inc | Solution | Intramuscular | NA | NA |
| 1771 | Th1186 | Human rabies virus immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Imogam Rabies Pasteurized | Sanofi Pasteur Limited | Solution | Intramuscular | NA | NA |
| 1774 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Hyperrho S/d Mini-dose | GRIFOLS USA, LLC | Solution | Intramuscular | NA | NA |
| 1775 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Micrhogam Ultra-filtered Plus | Kedrion Melville, Inc. | Injection, Solution | Intramuscular | NA | NA |
| 1776 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Rhogam Ultra-filtered Plus | Kedrion Melville, Inc. | Injection, Solution | Intramuscular | NA | NA |
| 1777 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Rhophylac | Csl Behring Ag | Solution | Intramuscular; Intravenous | NA | NA |
| 1785 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Kedrion Biopharma, Inc. | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1786 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Bivigam | Biotest Pharmaceuticals Corporation | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1788 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Carimune Nanofiltered | Csl Behring Ag | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1791 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Flebogamma Dif | GRIFOLS USA, LLC | Injection, Solution | Intravenous | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1797 | Th1191 | Vedolizumab | Heavy Chain Sequence Full view | 716 | IIa | Immunological Disorders | Entyvio | Takeda Pharmaceuticals America, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunosupressive agent, Antineoplastic agent | Integrin alpha-4, Integrin beta-7 |
| 1798 | Th1192 | Ustekinumab | NA Full view | 0 | IIIb | Infectious Disease | Stelara | Janssen Biotech, Inc. | Solution fro Injection | Subcutaneous | Deramtologic agent, Immunosuppressive agent, antineoplastic agent | Interleukin-12 subunit beta |
| 1800 | Th1194 | Tuberculin Purified Protein Derivative | NA Full view | 0 | IV | Infectious Disease | Aplisol | Par Pharmaceutical, Inc. | Solution for Injection | Intradermal | NA | NA |
| 1801 | Th1195 | Simoctocog Alfa | NA Full view | 0 | Ia | Hematological Disorders | Nuwiq | Octapharma Pharmazeutika Produktionsges M B H | Powder and solvent for Solution | Intravenous infusion | Antihaemorrhagics: blood coagulation factor VIII | NA |
| 1803 | Th1197 | Sebelipase alfa | SGGKLTAVDPETNMNVSEII Full view | 378 | Ia | Genetic Disorders | Kanuma | Alexion Pharmaceuticals, Inc. | Aqueous Solution | Intravenous infusion | Enzymes | NA |
| 1804 | Th1198 | Sacrosidase | NA Full view | 0 | Ia | Genetic Disorders | Sucraid | QOL Medical, LLC | Solution | Oral | Enzymes | NA |
| 1805 | Th1199 | Ramucirumab | ramucirumab|Homo sap Full view | 909 | IIIc | Cancer | Cyramza | Eli Lilly and Company | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Vascular endothelial growth factor receptor 2 |
| 1809 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Octaplex | Octapharma | Powder and solvent for Solution | Intravenous | NA | NA |
| 1812 | Th1203 | Peginterferon beta-1a | NA Full view | 0 | Ia | Neurological Disorder | Plegridy | Biogen Canada Inc | Sterile Solution | Subcutaneous | NA | |
| 1816 | Th1207 | Necitumumab | NA Full view | 0 | IIIc | Cancer | Portrazza | Eli Lilly and Company | Sterile, preservative free, clear to slightly opalescent and colorless to slightly yellow Solution | Intravenous | NA | NA |
| 1817 | Th1208 | Metreleptin | MVPIQKVQDDTKTLIKTIVT Full view | 147 | Ib | Adjunct therapy | Myalept | Amylin Pharmaceuticals, LLC | Lyophilized Powder for Solution | Subcutaneous | Leptin receptor | |
| 1818 | Th1209 | Methoxy polyethylene glycol-epoetin beta | NA Full view | 0 | Ib | Hematological Disorders | Mircera | Genentech, Inc. | Solution for Injection | Intravenous | NA | |
| 1820 | Th1211 | Ixekizumab | NA Full view | 0 | Ic | Infectious Disease | Taltz | Eli lilly | Sterile, preservative free, clear and colorless to slightly yellow Solution | Subcutaneous | NA | NA |
| 1822 | Th1213 | Insulin Degludec | Insulin degludec dif Full view | 0 | Ia | Metabolic Disorders | Tresiba | Novo Nordisk | sterile, aqueous, clear, and colorless Solution | Subcutaneous | NA | NA |
| 1829 | Th1219 | Anti-thymocyte Globulin (Rabbit) | NA Full view | 0 | IIIb | Immunological Disorders | ATG-Fresenius | Genzyme Inc. | Concentrate for solution for infusion. | Intravenous | Antibody | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |
| 1830 | Th1220 | Brodalumab | NA Full view | 0 | IIa | Immunological Disorders | Siliq | NA | sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution | Subcutaneous | Antineoplastic and Immunomodulating Agents | Interleukin 17 receptor A |
| 1831 | Th1221 | C1 Esterase Inhibitor (Recombinant) | NA Full view | 0 | IIa | Cardiac Disorders | Ruconest | Tjoapack Netherlands Bv | Powder and liquid for solution | Intravenous | Blood and Blood Forming Organs | Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
| 1833 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Ovidrel | Emd Serono | Injection, solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
| 1834 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Pregnyl | Physicians Total Care, Inc. | Injection, Solution | Intramuscular, Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
| 1835 | Th1224 | Chorionic Gonadotropin (Recombinant) | Alpha chain : APDVQD Full view | 237 | Ia | Hormonal Disorders | Ovitrelle | Merck Serono Europe Limited | powder and solvent to be made up into a solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor |
| 1836 | Th1225 | Coagulation factor X human | NA Full view | 0 | Ib | Hematological Disorders | Coagadex | NA | powder and solvent used to make a solution | Intravenous | Blood Coagulation Factors | NA |